Bellicum Pharmaceuticals
A clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders.
Market cap
$787k
Enterprise value
($45m)
Share price
$0.07 BLCM
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor | €0.0 | round |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
$94.4m | Series C | ||
| Total Funding | 000k | ||
| USD | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 |
| % growth | - | (93 %) | 1140 % | (76 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (954 %) | (10717 %) | (393 %) | (1929 %) |
| Profit | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1575 %) | (1544 %) | (157 %) | (1665 %) |
| EV | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 903 % | 7810 % | 380 % | 1518 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.